Johnson & Johnson Partners with Concerto HealthAI to Accelerate Oncology Drug Development Using AI Platform eurekaHealth 3.0

According to Leiphone, pharmaceutical giant Johnson & Johnson (Janssen) announced a collaboration with AI-driven precision oncology company Concerto HealthAI to advance drug development for multiple diseases. Prior to this partnership, Bristol-Myers Squibb and Pfizer had already established collaborations with Concerto HealthAI.

Dr. Jeff Elton, CEO of Concerto HealthAI, stated, “We are delighted that our new eurekaHealth product is providing support to Johnson & Johnson’s researchers and data scientists in drug development. As a leader in medical AI within the field of precision oncology, our company’s mission is highly aligned with Johnson & Johnson’s focus on innovative research in medical science.”

In future collaborations, Johnson & Johnson will utilize Concerto HealthAI’s research platform, “eurekaHealth 3.0,” to study real-world EMR data. Launched by Concerto HealthAI in January of this year, eurekaHealth 3.0 is currently the only oncology precision AI solution compliant with FDA 21 CFR Part 11 standards.

eurekaHealth is a SaaS platform (Software as a Service) featuring a flexible microservices architecture that optimizes operational performance, enables comparison of queues across different datasets, and supports integration into existing workflows (including both primary and third-party data).

eurekaHealth provides instant access to Concerto HealthAI data products designed to meet specialized requirements, including:

Data source: Reference [4]; Chart created by the WuXi AppTec Content Team

In previous collaborations with pharmaceutical companies on oncology drug development, eurekaHealth has been proven to help researchers reduce the time spent on feasibility analysis and study design by 50%.

The training data for eurekaHealth’s AI models are primarily sourced from the American Society of Clinical Oncology’s CancerLinQ initiative, as well as clinical healthcare data from other U.S. institutions.

Concerto HealthAI

Concerto HealthAI, headquartered in Boston, is currently a unicorn enterprise applying artificial intelligence technology in the field of precision oncology. The company recently completed a $150 million Series B financing round, with investors including Maverick Ventures, AllianceBernstein PCI, and SymphonyAI Group.

Leifeng.com learned that the financing announcement showed Concerto HealthAI's business revenue increased by 90% year-on-year. The new funding will help the company focus on developing new products, expanding from precision oncology to more therapeutic areas, and unlocking greater commercial value.

In March 2019, Bristol-Myers Squibb entered into a multi-year collaboration with Concerto HealthAI to jointly leverage real-world oncology data and advanced AI technologies for pharmaceutical research and development.

In April 2019, Pfizer announced a partnership with Concerto HealthAI, which will leverage real-world datasets and artificial intelligence technologies to assist Pfizer in developing new treatment regimens for hematologic malignancies.Leiphone(WeChat Official Account: Leiphone)

Original article by Leifeng.com; reproduction without authorization is prohibited. For details, seeReprint Guidelines。